Visceral leishmaniasis is associated with marked changes in serum lipid profile

European Journal of Clinical Investigation

Volumn 44, Issue 8, 2014, Pages 719-727

  Liberopoulos, Evangelos N ^a   Apostolou, Fotini ^a   Gazi, Irene F ^a   Kostara, Christina ^a   Bairaktari, Eleni T ^a   Tselepis, Alexandros D ^b   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherosclerosis; Infection; Leishmaniasis; Lipid profile; Lipoproteins

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; C REACTIVE PROTEIN; CARBOXYLESTERASE; CHOLESTEROL; CYTOKINE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; MALE; NEUTROPHIL; OBSERVATIONAL STUDY; PARTICLE SIZE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL LEISHMANIASIS; BLOOD; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PARASITOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOKINES; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; LIPID METABOLISM; LIPID METABOLISM DISORDERS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84904540004     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12288     Document Type: Article

References (45)

1. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-96.
2. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462-72.
3. Apostolou F, Gazi IF, Kostoula A, Tellis CC, Tselepis AD, Elisaf M et al. Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res 2009;50:2532-9.
4. Apostolou F, Gazi IF, Lagos K, Tellis CC, Tselepis AD, Liberopoulos EN et al. Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes. Atherosclerosis 2010;212:607-13.
5. Trimoreau F, Francois B, Desachy A, Besse A, Vignon P, Denizot Y. Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome. Mediators Inflamm 2000;9:197-200.
6. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 2003;44:780-92.
7. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
8. Gazi IF, Apostolou FA, Liberopoulos EN, Filippatos TD, Tellis CC, Elisaf MS et al. Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. Lipids 2011;46:953-60.
9. Rufail ML, Schenkein HA, Koertge TE, Best AM, Barbour SE, Tew JG et al. Atherogenic lipoprotein parameters in patients with aggressive periodontitis. J Periodontal Res 2007;42:495-502.
10. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003;168:107-13.
11. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18.
12. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;21:334-59.
13. Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis 2011;11:322-5.
14. Nieto CG, Barrera R, Habela MA, Navarrete I, Molina C, Jimenez A et al. Changes in the plasma concentrations of lipids and lipoprotein fractions in dogs infected with Leishmania infantum. Vet Parasitol 1992;44:175-82.
15. Vasconcellos RC, Urago KP, Bunn-Moreno MM, Madeira ED. Suppressor activity in Leishmania donovani-infected hamster serum: reversion by delipidated bovine serum albumin and role in cell cycle events. Braz J Med Biol Res 1996;29:615-22.
16. Bekaert ED, Dole E, Dubois DY, Bouma ME, Lontie JF, Kallel R et al. Alterations in lipoprotein density classes in infantile visceral leishmaniasis: presence of apolipoprotein SAA. Eur J Clin Invest 1992;22:190-9.
17. Kallel R, Bekaert ED, Dubois DY, Alcindor LG, Ayrault-Jarrier M, Mebazza A. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis. Clin Physiol Biochem 1993;10:8-12.
18. Liberopoulos E, Alexandridis G, Bairaktari E, Elisaf M. Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci 2002;32:305-8.
19. Bertoli A, Greco AV, Caputo S, Caradonna P, Grieco A, Laghi V. Visceral leishmaniasis presenting with hypertrigliceridaemia. Lancet 1982;2:504-5.
20. Soares NM, Leal TF, Fiuza MC, Reis EA, Souza MA, Dos-Santos WL et al. Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages. Parasite Immunol 2010;32:259-66.
21. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
22. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73.
23. Kusuoka H, Hoffman JI. Advice on statistical analysis for Circulation Research. Circ Res 2002;91:662-71.
24. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43:917-24.
25. Fraunberger P, Hahn J, Holler E, Walli AK, Seidel D. Serum cholesterol levels in neutropenic patients with fever. Clin Chem Lab Med 2002;40:304-7.
26. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359-66.
27. Gierens H, Nauck M, Roth M, Schinker R, Schurmann C, Scharnagl H et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000;20:1777-83.
28. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 1994;14:8-13.
29. Agouridis AP, Liberopoulos EN, Kostapanos MS, Elisaf MS. New-onset extremely low levels of high-density lipoprotein cholesterol. J Clin Lipidol 2012;6:593-5.
30. van Leeuwen HJ, van Beek AP, Dallinga-Thie GM, van Strijp JA, Verhoef J, van Kessel KP. The role of high density lipoprotein in sepsis. Neth J Med 2001;59:102-10.
31. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001;29:1563-8.
32. Jin W, Sun GS, Marchadier D, Octtaviani E, Glick JM, Rader DJ. Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circ Res 2003;92:644-50.
33. Feingold KR, Hardardottir I, Grunfeld C. Beneficial effects of cytokine induced hyperlipidemia. Z Ernahrungswiss 1998;37(Suppl 1):66-74.
34. Ly H, Francone OL, Fielding CJ, Shigenaga JK, Moser AH, Grunfeld C et al. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res 1995;36:1254-63.
35. Ribalta J, Vallve JC, Girona J, Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003;6:177-87.
36. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996;37:693-707.
37. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009;50(Suppl):S183-8.
38. Liberopoulos E, Apostolou F, Elisaf M. Serum lipid profile in patients with severe leptospirosis. Nephrol Dial Transplant 2004;19:1328-9; author reply 9-30.
39. Rufail ML, Schenkein HA, Barbour SE, Tew JG, van Antwerpen R. Altered lipoprotein subclass distribution and PAF-AH activity in subjects with generalized aggressive periodontitis. J Lipid Res 2005;46:2752-60.
40. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005;11:7351-4.
41. Parra S, Alonso-Villaverde C, Coll B, Ferre N, Marsillach J, Aragones G et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2007;194:175-81.
42. Aslan M, Nazligul Y, Horoz M, Bolukbas C, Bolukbas FF, Gur M et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 2008;196:270-4.
43. Mooser V, Berger MM, Tappy L, Cayeux C, Marcovina SM, Darioli R et al. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol 2000;20:1137-42.
44. Narahara H, Johnston JM. Effects of endotoxins and cytokines on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages. Am J Obstet Gynecol 1993;169:531-7.
45. Varma N, Naseem S. Hematologic changes in visceral leishmaniasis/kala azar. Indian J Hematol Blood Transfus 2010;26:78-82.